Navigation Links
Meda Introduces EDLUAR(TM), the First and Only Sublingual Tablet That Contains the Most Prescribed Sleep Medication, Zolpidem Tartrate
Date:9/8/2009

d nervousness.

You are encouraged to report side effects of prescription drugs to the Food and Drug Administration (FDA). Please visit www.fda.gov/medwatch or call 1-800-FDA-1088 or contact Meda Pharmaceuticals Inc. at 1-800-526-3840.

MEDA AB (publ) is a leading international specialty pharma company. Meda's products are sold in 120 countries worldwide and the company is represented by its own organizations in more than 40 countries. The Meda share is listed under Large Cap on the Nasdaq OMX Nordic Stock Exchange in Stockholm. Find out more, visit www.meda.se.

Ambien(R) is a registered trademark of sanofi-aventis US LLC.

(1) National Sleep Foundation 2005 "Sleep in America" Poll


'/>"/>
SOURCE Meda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Rodgers Introduces SamarionSolution to International Audience
2. Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
3. Emerson Ecologics Introduces the Emerson Quality Partner(TM) Program
4. Nuvilex Introduces Last Shot Hangover Remedy(TM) Video
5. EcoActive Surfaces Introduces OxiTitan VLR: New Light Powered Antimicrobial Coating Effective Against Viruses and Bacteria Indoors
6. American Community Introduces Latitude(TM) Health Plan for Employer Groups in Nebraska
7. Confidential Online STD Testing Clinic, getSTDtested.com, Introduces Edu-Tainment for STD Prevention as Social Networking Changes Dating Scene
8. babyUV/kidsUV inc. Introduces Its kidsUV Surf Team Line of Sun Protection Swim Wear
9. ConnextionsHealth Introduces Turnkey, Rapid Ramp Call Verification Solution
10. Motorola Introduces Innovative Wireless LAN Security Solution for Remote Wireless Security Testing
11. Verizon Introduces New IT Security Capabilities for Health Care Industry
Post Your Comments:
*Name:
*Comment:
*Email: